Enforcers shouldn't be 'bound by past' on theories of merger harm, US FTC official says in pharma discussion

Summary

The US Federal Trade Commission wants businesses to have clarity on its approach to merger enforcement at least in part to deter bad deals, but enforcers can't be "bound by the past" on potential theories of harm, an FTC adviser to the acting chair said today during a discussion on pharmaceutical deals.